A retrospective epidemiological study of screening-derived solid cancer incidence proxy rates in South Korea before and after COVID-19 using Korean National Health Insurance Service data
- 1Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea
Abstract
Background: The COVID-19 pandemic disrupted cancer screening and diagnostic pathways globally. Aggregate screening-derived indicators require cautious interpretation because they do not represent confirmed cancer registry incidence but might reflect program participation, referral patterns, and denominator composition. Objective: To evaluate pre- and post-COVID-19 changes in selected solid cancer screening-derived incidence proxy rates in South Korea, and to estimate model-based proxy rates through 2028. Methods: This retrospective ecological longitudinal study analyzed publicly available aggregate annual cancer-screening statistics from the Korean National Health Insurance Service (NHIS) and Korean Statistical Information Service (KOSIS) for six solid cancer programs (stomach, liver, colorectal, breast, cervical, and lung cancer). Annual proxy rates per 100,000 screened or eligible persons were calculated. Pre-COVID (2010–2019) and post-COVID (2020–2024) means were compared using Welch t-tests with Mann–Whitney U sensitivity analyses. Ordinary least-squares (OLS) forecasts were generated for 2025–2028. Interrupted time-series analysis was not feasible owing to an insufficient post-COVID observation window. Results: Post-COVID changes in proxy rates were heterogeneous across selected programs. Breast cancer proxy rates increased by 17.1% (Welch p = 0.002) and liver cancer proxy rates by 83.6% (Welch p = 0.002); the liver cancer increase reflects denominator restriction to a high-risk population rather than a true epidemiological surge. Stomach cancer decreased by 23.3% (Welch p = 0.001), cervical cancer by 56.9% (Welch p = 0.005), and colorectal cancer by 25.8% (Welch p = 0.007). Lung cancer data were available only from 2019 to 2024 (program inception) and were interpreted descriptively. Conclusions: Aggregate South Korean national screening data show pandemic-era temporal associations with heterogeneous changes in selected solid cancer program proxy rates. These findings support an indirect screening-disruption and ascertainment interpretation rather than causal proof of a direct COVID-19 effect on solid cancer incidence.
Related
- Rising active surveillance/observation rates and regimen intensification in young men: A retrospective cohort study of national commercial health insurance claims data
- Regional disparities in lung cancer surgery and survival in South Korea: a nationwide population-based retrospective cohort study using linked cancer registry and national health insurance data
- National incidence of coccidioidomycosis in the United States estimated through machine learning integration of epidemiological, veterinary, and socioecological data
- Epidemiological trend comparison and incidence prediction for elderly lung cancer in 204 countries and territories: a retrospective study.
- Epidemiological Characteristics and Incidence Trends of Hemorrhagic Fever With Renal Syndrome in Shandong Province, China: Retrospective Observational Study With Forecasting
BibTeX
@article{jung2026retrospective,
title = {{A retrospective epidemiological study of screening-derived solid cancer incidence proxy rates in South Korea before and after COVID-19 using Korean National Health Insurance Service data}},
author = {Hyeran Jung and Minsun Jung},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0360040},
url = {https://doi.org/10.1371/journal.pone.0360040},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A retrospective epidemiological study of screening-derived solid cancer incidence proxy rates in South Korea before and after COVID-19 using Korean National Health Insurance Service data
AU - Hyeran Jung
AU - Minsun Jung
PY - 2026
DA - 2026/10/16
JO - PLOS One
DO - 10.1371/journal.pone.0360040
UR - https://doi.org/10.1371/journal.pone.0360040
AB - Background: The COVID-19 pandemic disrupted cancer screening and diagnostic pathways globally. Aggregate screening-derived indicators require cautious interpretation because they do not represent confirmed cancer registry incidence but might reflect program participation, referral patterns, and denominator composition. Objective: To evaluate pre- and post-COVID-19 changes in selected solid cancer screening-derived incidence proxy rates in South Korea, and to estimate model-based proxy rates through 2028. Methods: This retrospective ecological longitudinal study analyzed publicly available aggregate annual cancer-screening statistics from the Korean National Health Insurance Service (NHIS) and Korean Statistical Information Service (KOSIS) for six solid cancer programs (stomach, liver, colorectal, breast, cervical, and lung cancer). Annual proxy rates per 100,000 screened or eligible persons were calculated. Pre-COVID (2010–2019) and post-COVID (2020–2024) means were compared using Welch t-tests with Mann–Whitney U sensitivity analyses. Ordinary least-squares (OLS) forecasts were generated for 2025–2028. Interrupted time-series analysis was not feasible owing to an insufficient post-COVID observation window. Results: Post-COVID changes in proxy rates were heterogeneous across selected programs. Breast cancer proxy rates increased by 17.1% (Welch p = 0.002) and liver cancer proxy rates by 83.6% (Welch p = 0.002); the liver cancer increase reflects denominator restriction to a high-risk population rather than a true epidemiological surge. Stomach cancer decreased by 23.3% (Welch p = 0.001), cervical cancer by 56.9% (Welch p = 0.005), and colorectal cancer by 25.8% (Welch p = 0.007). Lung cancer data were available only from 2019 to 2024 (program inception) and were interpreted descriptively. Conclusions: Aggregate South Korean national screening data show pandemic-era temporal associations with heterogeneous changes in selected solid cancer program proxy rates. These findings support an indirect screening-disruption and ascertainment interpretation rather than causal proof of a direct COVID-19 effect on solid cancer incidence.
SN - 1932-6203
ER -